TCGA-T2-A6WX-01A-12R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.047716895
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.740
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- MYC_TARGETS_V1+0.470
- OXIDATIVE_PHOSPHORYLATION+0.450
- MYC_TARGETS_V2+0.440
- DNA_REPAIR+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- COMPLEMENT+0.260
- E2F_TARGETS+0.260
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.490
- UV_RESPONSE_DN-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- MYOGENESIS-0.390
- ANDROGEN_RESPONSE-0.370
- ESTROGEN_RESPONSE_EARLY-0.320
- CHOLESTEROL_HOMEOSTASIS-0.270
- KRAS_SIGNALING_DN-0.270
- PROTEIN_SECRETION-0.240
- ANGIOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-UF-A7JT-01A-11R-A34R-07 | — | — | 0.903 |
| 2 | TCGA-F7-A61S-01A-11R-A28V-07 | — | — | 0.884 |
| 3 | TCGA-UF-A7JO-01A-11R-A34R-07 | — | — | 0.876 |
| 4 | fe769a85-08b2-4442-aa8f-2b587e49001d | — | — | 0.876 |
| 5 | a8cd01e2-f7f4-487c-8cde-4fcf21bfe0e7 | — | — | 0.858 |
| 6 | TCGA-F7-A620-01A-11R-A28V-07 | — | — | 0.849 |
| 7 | c63f3f74-14fa-4a9e-9925-30b0f5da7dd9 | — | — | 0.834 |
| 8 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.831 |
| 9 | TCGA-CV-A6JZ-01A-11R-A31N-07 | — | — | 0.820 |
| 10 | SRR12475171 | — | — | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.740 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |